What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD

Months after topline results from the CAFETERIA study demonstrated the ability to instill high levels of tolerance in children with high-threshold peanut allergy, questions remain about how its findings fit within traditional oral immunotherapy (OIT) goals and how it highlights the distinction between desensitization and sustained unresponsiveness.

The CAFETERIA study was highlighted in a session given by Scott H. Sicherer, MD, Director of the Elliot and Roslyn Jaffe Food Allergy Institute and the Elliot and Roslyn Jaffe Professor of Pediatric Allergy and Immunology at the Icahn School of Medicine at Mount Sinai, at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania.

sat down with Sicherer to discuss how clinicians should interpret the study’s results in real-world practice. He noted that terms like “remission” and “sustained unresponsiveness” are often used loosely, but in research they are highly protocol-specific. In many OIT trials, sustained unresponsiveness is defined by a relatively short avoidance period of often 6 weeks before re-challenge. In CAFETERIA, the team sought to mirror a more realistic scenario. After children demonstrated the ability to tolerate the equivalent of a peanut butter sandwich, they were asked to incorporate peanut more naturally into their diets for 16 weeks, consuming modest amounts weekly rather than adhering to a strict daily regimen. Only after that period were they instructed to completely avoid peanut for eight weeks before undergoing a final oral food challenge.

Most participants maintained tolerance after that extended, real-world–informed approach. Still, Sicherer is cautious about framing the results as a “cure.” In practice, he continues to counsel families that ongoing ingestion is important. Even if 1 to 2 tablespoons per week appears sufficient to maintain benefit, prolonged avoidance could allow clinical reactivity to return. For that reason, he advises continued dietary inclusion and routine follow-up rather than declaring the allergy resolved.

While CAFETERIA was a single-site study can not be generalized across food allergies, Sicherer believes the core principle of the study, that individuals with lower baseline IgE levels and higher initial tolerance thresholds may respond more readily to low-intensity OIT, likely extends beyond peanut. The concept may be applicable to other common allergens such as milk, egg, or tree nuts and would benefit from broader replication. Whether larger, multi-center trials will test that hypothesis remains to be seen, but the phenotype-driven approach introduced by CAFETERIA may signal a broader evolution in food allergy management.

“There's nothing so special about peanut. In fact, it might be that peanut would have been a harder case to approach. So would this apply to egg or milk or or other nuts and just other foods in general? I think the answer is yes. But are the studies going to be done? We'll wait and see,” Sicherer said.

Sicherer SH, Bunyavanich S, Berin MC, et al. Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy. 

. Published online February 10, 2025. doi: 10.1056/evidoa2400306

Sicherer S. FAED Presents: The Potential for Tolerance After Oral Immunotherapy in High-Threshold Patients: The CAFETERIA Study. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Session 1705.

Videos

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy. 

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The United States (US) Food and Drug Administration (FDA) has granted accelerated approval to navepegritide (YUVIWEL), a once-weekly C-type natriuretic peptide (CNP) analog, to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. The decision was based on improvements in annualized growth velocity (AGV) from 3 phase 3 trials, with continued approval contingent on confirmatory evidence of clinical benefit.

“The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, said in Ascendis Pharma’s statement.

 “My goal is to help children and parents develop care plans tailored to their individual needs and objectives, and I look forward to adding YUVIWEL to my discussions with them.”

Achondroplasia, the most common form of disproportionate short stature, is caused by activating variants in fibroblast growth factor receptor 3 (FGFR3), resulting in impaired endochondral ossification. Beyond short stature, affected individuals face increased risks of foramen magnum stenosis, spinal stenosis, sleep-disordered breathing, and other neurologic and orthopedic complications.

 Therapeutic strategies have focused on modulating the overactive FGFR3 pathway, including use of CNP analogs to counterbalance signaling at the growth plate.

“Little People of America, the largest national advocacy and support organization for people with dwarfism, is committed to ensuring that the voices of people with dwarfism remain central in conversations about research and medical options such as YUVIWEL,” said the Board of Directors of Little People of America.

 “We champion dwarf and disability pride, advocate for inclusion and respect, and foster open dialogue across diverse perspectives. Our goal is to empower individuals and families to make healthcare decisions that reflect their own values and experiences, while pushing for research efforts and new treatment options such as this that could have the potential to support outcomes that truly matter to our community.”

The FDA’s decision was supported by 3 randomized, double-blind, placebo-controlled trials of navepegritide, including the pivotal phase 3 ApproaCH study, as well as open-label extension data of up to 3 years. Detailed results from the phase 3 trial have been published in 

 In that study, once-weekly navepegritide significantly increased AGV compared with placebo in children with achondroplasia. The most commonly reported adverse events (AEs) were injection-site reactions and mild, transient hypotension; serious AEs were infrequent.

Navepegritide was approved under the accelerated approval pathway based on increased AGV as a surrogate outcome reasonably likely to predict clinical benefit. Confirmatory trials will be required to verify longer-term functional outcomes, such as adult height, complication rates, or quality-of-life measures.

“We are confident in YUVIWEL’s potential to transform the treatment of achondroplasia and are deeply grateful to patients, clinicians, and advocates for their many contributions to this important milestone,” Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma, added.

 “We have listened to advocacy groups for people with dwarfism to ensure we address what the community actually cares about. This reflects our ongoing commitment to pursue outcomes that patient communities have told us are important to them, and gives the achondroplasia community a new way to look at the promise of pharmacological treatment options.”

 C-type natriuretic peptide analog (prodrug)

 Increase linear growth in children ≥2 years with achondroplasia and open epiphyses

 FDA accelerated approval (February 2026)

 Increased annualized growth velocity vs placebo

 Injection-site reactions; transient hypotension

CNP is an endogenous peptide that promotes endochondral bone growth by antagonizing the MAPK pathway downstream of FGFR3. By enhancing CNP signaling, navepegritide aims to offset the constitutive FGFR3 activation characteristic of achondroplasia. As with other CNP analogs, blood pressure monitoring is recommended given the peptide’s vasodilatory properties.

Until 2021, management of achondroplasia was largely supportive and surgical. In November 2021, the FDA approved vosoritide, a daily CNP analog, to increase growth velocity in children with open growth plates.

 Vosoritide demonstrated an approximate 1.6 cm/year increase in AGV compared with placebo in a phase 3 trial.

Navepegritide represents an alternative CNP-based approach, designed as a prodrug to provide sustained systemic CNP exposure over a weekly dosing interval. Whether once-weekly dosing translates into differences in adherence, tolerability, or long-term outcomes compared with daily therapy remains to be established in comparative studies.

As with vosoritide, the clinical relevance of increased childhood growth velocity to long-term morbidity—such as need for orthopedic procedures, neurologic complications, or adult functional status—remains under investigation. 

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. News release. Ascendis Pharma. February 27, 2026. 

https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children

Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. 

. 2026;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771

US Food and Drug Administration. FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism. News release. November 19, 2021. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism

Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. 

. 2024;8(1):40-50. doi:10.1016/S2352-4642(23)00265-1

Articles

FDA accelerated approval was granted to once-weekly navepegritide (YUVIWEL), a C-type natriuretic peptide analog, for children ≥2 years with achondroplasia and open epiphyses to increase linear growth. Approval was supported by three randomized, double-blind, placebo-controlled phase 3 trials, including APPROACH, plus open-label extensions up to three years, demonstrating increased annualized growth velocity. Mechanistically, augmented CNP signaling counterbalances FGFR3-driven MAPK overactivity at the growth plate. Common adverse events included injection-site reactions and mild, transient hypotension. Continued authorization requires confirmatory evidence linking growth gains to durable clinical benefit and patient-relevant outcomes.

Navepegritide, to be marketed as YUVIWEL, is the only FDA-approved treatment providing continuous CNP exposure over its weekly dosing interval.

FDA News

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD

Counseling families about treatment timelines in pediatric 

often centers on when meaningful itch relief can be expected, but emerging data on tapinarof cream now allows clinicians to incorporate anticipatory guidance around sleep improvement into those early discussions as well.

At the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in Philadelphia from February 27 - March 2, HCPLive spoke with Druhan Howell, MD, an allergist from Mobile, Alabama, on a recent pooled analysis of ADORING 1 and ADORING 2 examining sleep outcomes of once-daily tapinarof for 8 weeks in pediatric patients with moderate to severe AD.

The analysis showed that once daily tapinarof cream 1% (VTAMA), an US Food & Drug Administration (FDA)-approved nonsteroidal topical aryl hydrocarbon receptor agonist for AD, was associated with early and sustained improvements in sleep-related outcomes in children aged 2 – 17 years.

Investigators observed sleep improvements as early as 1 week. By week 8, children treated with tapinarof demonstrated greater mean improvements in POEM and DFI scores compared with those who received vehicle. This was observed across age groups 2 – 6 years (

For Howell, this alignment between itch reduction and sleep improvement provides a practical framework for expectation-setting. Families frequently present after prolonged periods of nocturnal scratching and fragmented sleep. Being able to counsel that both itch and sleep may begin to improve within the first week offers a tangible and time-bound treatment goal. She emphasized that sustained improvement through 8 weeks, along with a safety and tolerability profile consistent with earlier analyses, supports incorporating sleep into routine counseling.

Howell said the findings match up to what she sees in clinical practice, with tapinarof cream improving sleep.

“I've had patients who we are seeing, and they come back, and we're talking about how nice it is now that the kids are not up all night, scratching and itching, waking parents up, waking other siblings up that they share bedrooms with,” Howell said. “Those discussions [of sleep improvement] were already happening on the side in my clinic, but now I have some meaningful data that is representative of that clinical impact that I was already seeing.”

Reported disclosures for Howell include Organon, Dermavant Sciences, Inc., AstraZeneca Pharmaceuticals LP, Actelion Pharmaceuticals US, Inc., GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., CSL Behring, Takeda Pharmaceuticals U.S.A., Inc., Blueprint Medicines Corporation, Amgen Inc., Philips North America LLC, Pulmonx Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Grifols USA, LLC, Baxter Healthcare, Vifor Pharma, Inc., Mylan Specialty L.P., and more.

Boguniewicz M, Eichenfield LF, Kwong P, Hebert A. Improvement in sleep and family impact for pediatric patients down to 2 years of age with atopic dermatitis treated with tapinarof cream 1% once daily in two pivotal phase 3 trials. J Allergy Clin Immunol. 2026;157(2). 

https://www.jacionline.org/article/S0091-6749(25)XXXX-X/fulltext

Howell D. Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD. HCPLive. Published on February 27, 2026. Accessed on February 27, 2026. 

https://www.hcplive.com/view/tapinarof-cream-1-improves-sleep-atopic-dermatitis-druhan-howell-md

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Expanding specialty care beyond traditional academic campuses has become a critical strategy for improving access to advanced therapies for complex digestive diseases such as inflammatory bowel disease (IBD). However, geographic growth alone is insufficient without maintaining the clinical rigor, continuity, and innovation that define tertiary referral centers. Ensuring patients receive the same level of expertise regardless of location has become a defining priority for leading gastroenterology programs. In the accompanying video, Russell Cohen, MD, professor of medicine and clinical director of the Inflammatory Bowel Disease Center at the University of Chicago, described how UChicago Medicine’s expansion throughout the Chicagoland region has fundamentally improved access to subspecialty care. Historically, patients seeking advanced IBD management were required to travel to the Hyde Park campus. Today, University of Chicago faculty deliver care across a network spanning northern suburbs, western communities, and northwest Indiana. “We’re doing the driving to you,” Cohen said, emphasizing that patients seen at satellite locations receive care directly from University of Chicago specialists rather than affiliated providers without academic appointments. Maintaining consistency across sites has been central to the expansion strategy. Cohen noted that care delivery extends beyond outpatient visits to include procedures, inpatient management, infusion therapies, and clinical trial access—all coordinated through the same academic teams. This integrated model allows patients to transition seamlessly between community-based care and the university’s tertiary services while preserving continuity and expertise. “You’re getting the full monty with the University of Chicago,” he said, underscoring the program’s commitment to delivering comprehensive, academically grounded care throughout its network. At the same time, rapid therapeutic innovation has transformed clinical practice. Cohen reflected on the institution’s longstanding role in advancing biologic and targeted therapies, dating back to early breakthroughs in Crohn disease research and continuing through participation in modern clinical trials. These advances have expanded treatment options and improved outcomes, while ongoing translational research continues to connect laboratory discoveries with clinical application.

Expanding Access, Advancing Science- How the University of Chicago Is Redefining IBD Care Across Chicagoland

Expanding specialty care beyond traditional academic campuses has become a critical strategy for improving access to advanced therapies for complex digestive diseases such as inflammatory bowel disease (IBD). However, geographic growth alone is insufficient without maintaining the clinical rigor, continuity, and innovation that define tertiary referral centers. Ensuring patients receive the same level of expertise regardless of location has become a defining priority for leading gastroenterology programs.

, professor of medicine and clinical director of the Inflammatory Bowel Disease Center at the 

, described how UChicago Medicine’s expansion throughout the Chicagoland region has fundamentally improved access to subspecialty care. Historically, patients seeking advanced IBD management were required to travel to the Hyde Park campus. Today, University of Chicago faculty deliver care across a network spanning northern suburbs, western communities, and northwest Indiana. “We’re doing the driving to you,” Cohen said, emphasizing that patients seen at satellite locations receive care directly from University of Chicago specialists rather than affiliated providers without academic appointments.

Maintaining consistency across sites has been central to the expansion strategy. Cohen noted that care delivery extends beyond outpatient visits to include procedures, inpatient management, infusion therapies, and clinical trial access—all coordinated through the same academic teams. This integrated model allows patients to transition seamlessly between community-based care and the university’s tertiary services while preserving continuity and expertise. “You’re getting the full monty with the University of Chicago,” he said, underscoring the program’s commitment to delivering comprehensive, academically grounded care throughout its network.

At the same time, rapid therapeutic innovation has transformed clinical practice. Cohen reflected on the institution’s longstanding role in advancing biologic and targeted therapies, dating back to early breakthroughs in Crohn disease research and continuing through participation in modern clinical trials. These advances have expanded treatment options and improved outcomes, while ongoing translational research continues to connect laboratory discoveries with clinical application.

UChicago GI faculty bring expert endoscopy and IBD care closer to you, with seamless hospital follow-up and cutting-edge clinical trials.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved 3 new indications for Novo Nordisk’s once-weekly somapacitan-beco (Sogroya) injection 5 mg, 10 mg, or 15 mg.

With the approval, the long-acting growth hormone is now indicated for children ≥ 2.5 years of age with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age, or growth failure associated with Noonan Syndrome (NS). Somapacitan is additionally indicated for children ≥ 2.5 years of age and adults with growth hormone deficiency (GHD).

"Families and healthcare professionals now have the option to consider a once-weekly growth hormone as treatment with 313 injection free days per year for their children 2.5 years and older with ISS, NS, and born SGA," said Aristides Maniatis, MD, founder of Rocky Mountain Pediatric Endocrinology and an investigator in the REAL8 trial supporting the approvals. "[Somapacitan] is an effective alternative to daily injections that supports children's growth goals and may help fit into their routine."

Once-weekly somapacitan injection is a prescription human growth hormone analogue that has previously been approved in the US for the replacement of endogenous growth hormone in adults with growth hormone deficiency in August 2020 and for pediatric patients ≥ 2.5 years of age with growth failure due to inadequate secretion of endogenous growth hormone in April 2023.

The latest indications for children ≥ 2.5 years of age with ISS, short stature born SGA and with no catch-up growth by 2 years of age, and growth failure associated with NS were supported by data from the REAL8 study as part of the ongoing REAL clinical trial program.

The multi-center, randomized, open-label, active-comparator, phase 3 basket study is being conducted in growth hormone treatment-naïve, pre-pubertal pediatric patients with short stature born SGA, NS, or ISS. The primary treatment period was 52 weeks, and the study is currently in a 2-year safety extension phase. Of note, this is the first time a trial design of this type has been implemented in the growth disorder space.

In the study, 142 pediatric patients aged 2.6 to 10.7 years with SGA were randomly assigned to somapacitan 0.24 mg/kg/week (n = 70), once-daily somatropin 0.035 mg/kg/day (n = 37), or once-daily somatropin 0.067 mg/kg/day (n = 35). Additionally, 77 pediatric patients aged 2 to 11.1 years with NS were randomized to somapacitan 0.24 mg/kg/week (n = 49) or once-daily somatropin 0.05 mg/kg/day (n = 28), and 88 pediatric patients aged 2.8 to 10.8 years with ISS were randomized to 0.24 mg/kg/day (n = 60) or once-daily somatropin 0.05 mg/kg/day (n = 28).

As described in the press release, all 3 sub studies achieved their primary endpoint, demonstrating that once-weekly somapacitan injection 5 mg, 10 mg, or 15 mg was non-inferior to once-daily growth hormone treatment for mean annualized height velocity (AHV) at week 52.

Specifically, in children with ISS, somatropin demonstrated non-inferiority in mean AHV compared with daily somatropin (10.2 vs 10.5 cm/year). The dose of 0.05 mg/kg/day of daily somatropin is less than maximum dose approved dose (0.067 mg/kg/day) for use in pediatric patients in the US.1

In children born SGA with no catch up by 2 years of age, somatropin demonstrated non-inferiority compared to both daily growth hormone doses (0.035 mg/kg/day and 0.067 mg/kg/day) with a mean AHV of 11.0 cm/year vs 9.4 cm/year vs 11.1 cm year respectively; daily growth hormone dose of 0.035 mg/kg/day is less than the maximum approved dose (0.067 mg/kg/day) in the US.

In children with growth failure associated with NS, somatropin demonstrated non-inferiority in mean AHV compared to daily somatropin (10.4 vs 9.2 cm/year); the daily somatropin dose of 0.050 mg/kg/day used is less than the maximum approved dose (0.066 mg/kg/day) in the US.

In REAL8, the adverse reactions occurring in ≥10% of patients treated with somatropin across all 3 indications were respiratory tract infection, nasopharyngitis, ear infection, and diarrhea. Additional reactions occurring in ≥10% of patients treated with somatropin included headache in ISS and NS; cough, pyrexia, and vomiting in NS and SGA; and injection site reaction in ISS.

"Daily injections have defined the growth disorder treatment paradigm for more than 40 years. Our scientific leadership and focus on advancing care in rare diseases led us to the development of [somatropin] – a once‑weekly growth hormone therapy – which may help address the challenge of daily injections while offering patients and families a therapeutic option that delivers efficacy and safety," said Nicky Kelepouris, Rare Endocrine Disorders-US Medical Lead. "These new approvals expand the patient populations that can be helped by [somatropin] and reflect our strategic focus on delivering meaningful, evidence‑based innovation for children living with growth disorders."

Novo Nordisk additionally noted the submission of a supplemental application for somatropin for approval in the US for Turner Syndrome, with a decision expected later in 2026.

Novo Nordisk. FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications. February 27, 2026. Accessed February 27, 2026. 

https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-sogroya-as-the-first-and-only-once-weekly-long-acting-growth-hormone-for-three-additional-pediatric-indications-302699946.html

FDA. FDA approves weekly therapy for adult growth hormone deficiency. September 1, 2020. Accessed February 27, 2026. 

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weekly-therapy-adult-growth-hormone-deficiency

Fitch J. FDA expands approval of somapacitan-beco injection to children with growth hormone deficiency. Contemporary Pediatrics. May 1, 2023. Accessed February 27, 2026. 

https://www.contemporarypediatrics.com/view/fda-expands-approval-of-somapacitan-beco-injection-to-children-with-growth-hormone-deficiency#:~:text=%7CArticles%7CMay%201%2C%202023,for%20other%20growth%2Dassociated%20problems

FDA expanded somapacitan-beco (Sogroya) once-weekly long-acting GH to pediatric idiopathic short stature, short stature born small for gestational age without catch-up by age 2, and Noonan syndrome–associated growth failure, for children ≥2.5 years. Indications also include pediatric and adult GHD. Approvals were supported by REAL8, a multicenter, randomized, open-label, active-comparator phase 3 basket study in treatment-naïve, prepubertal children, showing noninferior annualized height velocity at week 52 versus daily somatropin across substudies. Safety signals were consistent with expected pediatric GH therapy.

The long-acting growth hormone is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, born Small for Gestational Age, or Noonan Syndrome.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

CAFETERIA: Expanding Treatment Pathways for High-Threshold Peanut Allergy, with Scott Sicherer, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These new data from the OLYMPIA open-label extension study highlight long-term safety and efficacy findings on nemolizumab (Nemluvio).

Nemolizumab Shows Long-Term Efficacy in Prurigo Nodularis for Up to 3 Years

Mohammad Anadani, MD, is the chief of neuroendovascular services for Intent Medical Group at the Endeavor Health Advanced Neurosciences Center.

Anadani discusses a recent study highlighting the myriad contributing factors in the steadily increasing risk of maternal stroke across the country.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Pregnancy-Related Maternal Stroke Increasing Across US, With Mohammad Anadani, MD

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Brown discusses a destigmatised future of obesity management in patients with kidney failure. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Destigmatizing Obesity in Kidney Failure Patients Seeking Transplants, With Adrian Brown, PhD

Bhatt discusses a recent study from GSK highlighting AREXVY’s efficacy in lowering major adverse cardiovascular events.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

RSV Vaccine Demonstrates Cardioprotective Effects, Reduces MACE and Hospitalizations, With Deepak Bhatt, MD, MPH

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Atherosclerotic Cardiovascular Disease

Expanding the Toolbox for Complex Aorta and Limb Salvage

Joselle Cook, MD, MBBS, is a hematologist and oncologist, specializing in Myeloma, Amyloid and Plasma cell disorders at the Mayo Clinic in Rochester Minnesota.

Panelist member explains new ASH guidelines aim to improve early diagnosis of AL amyloidosis with blood, urine, and biopsy testing.


Hematology

Key Insights on New ASH Guidelines for AL Amyloidosis, With Joselle Cook, MD

Manreet Kanwar, MD, outlines advances in heart failure care, rising medication complexity, and the need for integrated, patient-centered systems.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Comprehensive, Multidisciplinary Care for Complex Cardiac Disease

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.



Latest News

What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD

Expanding Access, Advancing Science- How the University of Chicago Is Redefining IBD Care Across Chicagoland

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)